Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
This study is the first time into human study (FTIH) for HYR-PB21 for injection. The study
will evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending
and single subcutaneous dose of HYR-PB21 for injection in healthy adult volunteers.The
results of this study are intended to be used to identify appropriate and well tolerated
doses of HYR-PB21 for injection to be used in further studies. A comparison of PK/PD
characteristics between HYR-PB21 for injection and EXPAREL will also be included in this
study.